Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lintuzumab-ac225 + cytarabine
- Development stage
- Unknown
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a **combination therapy** consisting of **lintuzumab-ac225** (a humanized monoclonal antibody targeting CD33, conjugated to the alpha-emitting radionuclide actinium-225) plus **cytarabine** (a nucleoside analog chemotherapy). Lintuzumab-ac225 delivers high-energy alpha radiation specifically to CD33-expressing myeloid cells, causing lethal double-strand DNA breaks and selective killing of leukemic blasts. Cytarabine acts as an antimetabolite, inhibiting DNA synthesis in rapidly dividing cells. This combination is being studied for treating patients with **acute myeloid leukemia (AML)**, including relapsed/refractory cases and elderly, previously untreated patients. The principal developer is **Actinium Pharmaceuticals**. Clinical trials demonstrate promising response rates and measurable residual disease (MRD) negativity in high-risk AML, particularly when used with other chemotherapeutic regimens.
- Brand names
- actimab-a
- Other names
- lintuzumab-Ac-225 + cytarabine
02
Targets
DNADNA polymerase familyCD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on lintuzumab-ac225 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lintuzumab-ac225 + cytarabine.